{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:59:18Z","timestamp":1793411958811,"version":"4.5.0"},"reference-count":78,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T00:00:00Z","timestamp":1595030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Interferon alfa was first used in the treatment of myeloproliferative neoplasms (MPNs) over 30 years ago. However, its initial use was hampered by its side effect profile and lack of official regulatory approval for MPN treatment. Recently, there has been renewed interest in the use of interferon in MPNs, given its potential disease-modifying effects, with associated molecular and histopathological responses. The development of pegylated formulations and, more recently, ropeginterferon alfa-2b has resulted in improved tolerability and further expansion of interferon\u2019s use. We review the evolving clinical use of interferon in essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). We discuss interferon\u2019s place in MPN treatment in the context of the most recent clinical trial results evaluating interferon and its pegylated formulations, and its role in special populations such as young and pregnant MPN patients. Interferon has re-emerged as an important option in MPN patients, with future studies seeking to re-establish its place in the existing treatment algorithm for MPN, and potentially expanding its use for novel indications and combination therapies.<\/jats:p>","DOI":"10.3390\/cancers12071954","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T06:38:55Z","timestamp":1595313535000},"page":"1954","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-0117","authenticated-orcid":false,"given":"Joan","family":"How","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"},{"name":"Division of Hematology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA 02115, USA"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,18]]},"reference":[{"key":"ref_1","first-page":"258","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc.Lond. Ser. B-Biol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0076-6879(81)78094-7","article-title":"[4] Production of interferon in human leukocytes from normal donors with the use of Sendai virus","volume":"78","author":"Cantell","year":"1981","journal-title":"Methods Enzymol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/285542a0","article-title":"Isolation and structure of a human fibroblast interferon gene","volume":"285","author":"Derynck","year":"1980","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1073\/pnas.77.12.7010","article-title":"Construction and identification of bacterial plasmids containing nucleotide sequence for human leukocyte interferon","volume":"77","author":"Maeda","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","first-page":"123","article-title":"High doses of natural \u03b1-interferon (\u03b1-IFN) in the treatment of multiple myeloma\u2014A pilot study from the Myeloma Group of Central Sweden (MGCS)","volume":"41","author":"Brenning","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.1992.tb04559.x","article-title":"Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia","volume":"80","author":"Habermann","year":"1992","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-\u03b1 therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon \u03b1-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2141.1994.tb08324.x","article-title":"The in vitro and in vivo effect of recombinant interferon \u03b1-2a on circulating haemopoietic progenitors in polycythaemia vera","volume":"87","author":"Castello","year":"1994","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V70.4.1014.1014","article-title":"Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia","volume":"70","author":"Cazzola","year":"1987","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF01697629","article-title":"Possible selective effects of Interferon \u03b1-2b on a malignant clone in a case of polycythemia vera","volume":"66","author":"Hino","year":"1993","journal-title":"Ann. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2002-07-2287","article-title":"Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin","volume":"101","author":"Liu","year":"2003","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A","article-title":"Polycythemia vera treated with recombinant interferon-alpha 2a: Evidence of a selective effect on the malignant clone","volume":"56","author":"Massaro","year":"1997","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Italian Cooperative Study Group on Chronic Myeloid Leukemia, Tura, S., Baccarani, M., Zuffa, E., Russo, D., Fanin, R., Zaccaria, A., and Fiacchini, M. (1994). Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia. New Engl. J. Med., 330, 820\u2013825.","DOI":"10.1056\/NEJM199403243301204"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon -2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: Friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","article-title":"Interferon-\u03b1 targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway","volume":"38","author":"Lu","year":"2010","journal-title":"Exp. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.4049\/jimmunol.135.4.2507","article-title":"Studies of interferon as a regulator of hematopoietic cell proliferation","volume":"135","author":"Raefsky","year":"1985","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","article-title":"Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1","volume":"96","author":"Wang","year":"2000","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFN\u03b1 activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.immunol.26.021607.090400","article-title":"The IRF Family Transcription Factors in Immunity and Oncogenesis","volume":"26","author":"Tamura","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/sj.leu.2402602","article-title":"Interferon-\u03b1 induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo","volume":"16","author":"Paquette","year":"2002","journal-title":"Leukemia"},{"key":"ref_30","first-page":"596","article-title":"Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia","volume":"111","author":"Chen","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Lindner","year":"2003","journal-title":"Apoptosis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/08916930903510963","article-title":"Interferon-\u03b1 as angiogenesis inhibitor: Learning from tumor models","volume":"43","author":"Bonanno","year":"2010","journal-title":"Autoimmunity"},{"key":"ref_33","unstructured":"Network, N.C.C. (2019, August 17). Myeloproliferative Neoplasms (Version 2.2019). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn_blocks.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.leukres.2014.06.019","article-title":"Interferon \u03b1-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation","volume":"38","author":"Huang","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cncr.11486","article-title":"Phase II study of ?2 interferon in the treatment of the chronic myeloproliferative disorders (E5487)","volume":"98","author":"Radin","year":"2003","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1002\/cncr.21086","article-title":"Interferon \u03b1 therapy for patients with essential thrombocythemia","volume":"103","author":"Saba","year":"2005","journal-title":"Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical toxicity of interferons in cancer patients: A review","volume":"4","author":"Quesada","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Manshouri","year":"2013","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kj\u00e6r, L., Cordua, S., Holmstr\u00f6m, M.O., Thomassen, M., A Kruse, T., Pallisgaard, N., Larsen, T.S., De Stricker, K., Skov, V., and Hasselbalch, H.C. (2016). Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165336"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41375-018-0295-6","article-title":"JAK2V617F but not CALR mutations confer increased molecular responses to interferon-\u03b1 via JAK1\/STAT1 activation","volume":"33","author":"Czech","year":"2018","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: A post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-Term Incidence of Hematological Evolution in Three French Prospective Studies of Hydroxyurea and Pipobroman in Polycythemia Vera and Essential Thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2018-99-111946","article-title":"Results of the Myeloproliferative Neoplasms\u2014Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)","volume":"132","author":"Mascarenhas","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2019-124865","article-title":"Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/blood-2018-99-111255","article-title":"Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial-a Randomized Controlled Phase III Clinical Trial","volume":"132","author":"Knudsen","year":"2018","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood.V128.22.479.479","article-title":"Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia","volume":"128","author":"Mascarenhas","year":"2016","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Pereira","year":"2012","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","article-title":"Loss of TET2 has dual roles in murine myeloproliferative neoplasms: Disease sustainer and disease accelerator","volume":"125","author":"Kameda","year":"2015","journal-title":"Blood"},{"key":"ref_56","unstructured":"(2020, June 14). Phase II Randomized Clinical Trial Comparing Ropeginterferon Versus Phlebotomy in Low-Risk Patients with Polycythemia Vera. Results of the Pre-Planned Interim Analysis. Available online: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/303391\/tiziano.barbui.phase.ii.randomized.clinical.trial.comparing.ropeginterferon.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dlb2602."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1182\/blood-2018-99-118584","article-title":"Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera \u2014 Final Phase I\/II Peginvera Study Results","volume":"132","author":"Gisslinger","year":"2018","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-\u03b1 may retard progression of early primary myelofibrosis: A preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"key":"ref_59","first-page":"1","article-title":"Minimal Residual Disease after Long-term Interferon-Alpha2 treatment. A Report on Hematological, Molecular, and Histomorphological Response Patterns in Ten Patients with Essential Thrombocythemia and Polycythemia Vera","volume":"57","author":"Rank","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: A French Intergroup of Myeloproliferative neoplasms (FIM) study","volume":"103","author":"Ianotto","year":"2017","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30679","article-title":"The effect of initial molecular profile on response to recombinant interferon-\u03b1 (rIFN\u03b1) treatment in early myelofibrosis","volume":"123","author":"Silver","year":"2017","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: An ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"ref_63","first-page":"1","article-title":"Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib","volume":"94","author":"Hasselbalch","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"S\u00f8rensen, A.L., Mikkelsen, S.U., Knudsen, T.A., Bj\u00f8rn, M.E., Andersen, C.L., Bjerrum, O.W., Brochmann, N., Patel, D.A., Gjerdrum, L.M.R., and El Fassi, D. (2019). Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: A phase II study. Haematologica.","DOI":"10.3324\/haematol.2019.235648"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2018-99-110785","article-title":"Ruxopeg, a Multi-Center Bayesian Phase 1\/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis","volume":"132","author":"Kiladjian","year":"2018","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/j.clml.2019.03.027","article-title":"Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms","volume":"19","author":"Mondello","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/17474086.2018.1506325","article-title":"Contemporary management of patients withBCR-ABL1-negative myeloproliferative neoplasms during pregnancy","volume":"11","author":"Griesshammer","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2019-127058","article-title":"Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera","volume":"134","author":"How","year":"2019","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2016-09-728006","article-title":"Risk of venous thromboembolism in pregnant women with essential thrombocythemia: A systematic review and meta-analysis","volume":"129","author":"Skeith","year":"2017","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1912666","DOI":"10.1001\/jamanetworkopen.2019.12666","article-title":"Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes","volume":"2","author":"Maze","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ajh.21508","article-title":"Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations","volume":"84","author":"Tefferi","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ejh.13167","article-title":"Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era","volume":"101","author":"Balsat","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000264183","article-title":"Pharmacokinetics of Interferon-Alpha in Pregnant Women and Fetoplacental Passage","volume":"10","author":"Pons","year":"1995","journal-title":"Fetal Diagn. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","article-title":"Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: Outcome and safety. A case series","volume":"101","author":"Beauverd","year":"2016","journal-title":"Haematologica"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/089033440001600308","article-title":"Transfer of Interferon Alfa Into Human Breast Milk","volume":"16","author":"Kumar","year":"2000","journal-title":"J. Hum. Lact."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1954\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:41Z","timestamp":1760176181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,18]]},"references-count":78,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["cancers12071954"],"URL":"https:\/\/doi.org\/10.3390\/cancers12071954","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,18]]}}}